Brought to you by 
BioSante Pharmaceuticals nets $45.1mm through FOPO
03 Aug 2011
Executive Summary
BioSante Pharmaceuticals Inc. (women’s health and cancer therapeutics) has netted $45.1mm through the follow-on public offering of 16mm common shares at $3. Some of the funds will be used to continue Phase III studies of LibiGel, a once-daily transdermal testosterone gel for hypoactive sexual desire disorder in women.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Transdermal
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioSante Pharmaceuticals nets $45.1mm through FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice